Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Monks, N R, Calvete, J A, Curtin, N J, Blakey, D C, East, S J, Newell, D R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363482/
https://www.ncbi.nlm.nih.gov/pubmed/10901381
http://dx.doi.org/10.1054/bjoc.2000.1240
Descripción
Sumario:ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. © 2000 Cancer Research Campaign

Ejemplares similares